Translational lung cancer research
Adjuvant alectinib versus crizotinib in completely resected ALK-positive non-small-cell lung cancer: a real-world retrospective cohort study
By Yang Y, Liang S, Liu R and 3 others.
Abstract
Background
Following the phase III ALINA trial, adjuvant alectinib has become an important option for completely resected anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). However, the adjuvant role of crizotinib remains uncertain, and real-world data directly comparing adjuvant alectinib with crizotinib are limited. We compared their efficacy, central nervous system (CNS) control, and safety in this setting.
Methods
This single-center retrospective cohort study included 48 patients with R0-resected stage IA-IIIB ALK-positive NSCLC who underwent surgery between April 2012 and October 2023. Patients received alectinib 600 mg twice daily (n=26) or crizotinib 250 mg twice daily (n=22) after surgery. The primary endpoint was the 3-year disease-free survival (DFS) rate. Survival outcomes were estimated using the Kaplan-Meier method, and unadjusted hazard ratios (HRs) were calculated using Cox regression. Safety was evaluated by treatment-related adverse events.